Ligand Pharmaceuticals Inc
NASDAQ:LGND
Ligand Pharmaceuticals Inc
Revenue
Ligand Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Ligand Pharmaceuticals Inc
NASDAQ:LGND
|
Revenue
$131.3m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
10%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Ligand Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Ligand Pharmaceuticals Inc
Breakdown by Segments
Ligand Pharmaceuticals Inc
Total Revenue:
131.3m
USD
|
Royalties:
83.9m
USD
|
Captisol:
28.4m
USD
|
Contract:
19m
USD
|
See Also
What is Ligand Pharmaceuticals Inc's Revenue?
Revenue
131.3m
USD
Based on the financial report for Dec 31, 2023, Ligand Pharmaceuticals Inc's Revenue amounts to 131.3m USD.
What is Ligand Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
10%
Over the last year, the Revenue growth was -33%. The average annual Revenue growth rates for Ligand Pharmaceuticals Inc have been -11% over the past three years , -12% over the past five years , and 10% over the past ten years .